At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Enteral Immunonutrition During Chemoradiotherapy in Patients With Head and Neck Cancer or Esophageal Cancer
In Brief
A Phase 4 clinical trial evaluating Impact (R) Enteral Nutrition and impact for Malnutrition and 2 related conditions. Completed, enrolled 250 participants across 1 site.
Detailed Summary
The aim of this study is to investigate if enteral immunonutrition of head and neck or esophageal cancer patients, using an arginine, omega 3 fatty acid, nucleotides-enhanced diet \[Impact (R), Novartis\] versus a standard enteral nutrition (control, Novartis), could improve clinical outcomes (mucositis frequency, treatment tolerance), nutritional and immune status, and life quality parameters.
Study Details
Timeline
Interventions
mucositis frequency, treatment tolerance
1500 calories every day : -5 days before the begining of the chemoradiotherapy and until the last day of the treatment